Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,335,422 shares of the company's stock after acquiring an additional 300,000 shares during the period. Teva Pharmaceutical Industries accounts for approximately 5.7% of Migdal Insurance & Financial Holdings Ltd.'s investment portfolio, making the stock its biggest holding. Migdal Insurance & Financial Holdings Ltd. owned about 2.32% of Teva Pharmaceutical Industries worth $404,775,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after buying an additional 22,044,407 shares during the last quarter. FMR LLC grew its holdings in Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Duquesne Family Office LLC boosted its position in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after purchasing an additional 5,186,592 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Teva Pharmaceutical Industries by 416.0% during the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after buying an additional 4,824,247 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

TEVA has been the topic of several recent analyst reports. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus price target of $24.71.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.23 during trading on Friday, hitting $16.08. The stock had a trading volume of 12,142,802 shares, compared to its average volume of 10,324,962. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The company's 50-day moving average price is $17.01 and its two-hundred day moving average price is $16.97. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock has a market capitalization of $18.44 billion, a P/E ratio of -13.98, a PEG ratio of 0.96 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter last year, the business posted $0.48 earnings per share. The business's quarterly revenue was up 1.9% compared to the same quarter last year. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.